June 12, 2008 |
Encorium Group Inc., a clinical research organization based in Wayne, will expand its global reach by combining with Fine Success Investments Ltd., a British Virgin Islands company doing business as Linkcon, Encorium said. Linkcon has acquired or is acquiring clinical research organizations in China, India and Latin America. Linkcon also holds a controlling interest in JK1, a health-care portal for medical professionals and consumers that links China and the western world. Encorium also announced that it is buying Prologue Research International Inc. for $13 million.
August 29, 2005
After reading Chris Mondics' excellent article on the pharmaceutical hub in the Philadelphia area, I was surprised and disappointed to read the Aug. 23 editorial "Find the right remedy," which was so negative toward Merck, Vioxx and the Food and Drug Administration. Merck is the biggest component of our area's pharmaceutical hub and an important aspect of the local economy with its 12,000 well-paid employees. It still has a reputation for competence and integrity in research and development.
September 2, 2009 |
Encorium Group Inc., which performs clinical research, has been warned that its stockholders' equity does not comply with Nasdaq listing requirements. The letter, which the Berwyn company received Aug. 25, said that, based on its 10-Q for the quarter ended June 30, it didn't have the $2.5 million stockholders' equity required for continued listing on Nasdaq's Capital Market. Encorium's 10-Q showed shareholders' equity at $1.8 million. The company, which specializes in designing and managing trials of new products for the pharmaceutical industry, said it intended to submit a compliance play by the Sept.
August 17, 2010
Encorium Group Inc., a Wayne-based company that sold its U.S. assets a year ago, said Wednesday that it had a second-quarter net loss of $0.81 million, or 24 cents per share, compared with a loss of $1.94 million, or 76 cents per share for the same period a year ago. Total revenue for the three months ending June 30 was $4.39 million, compared with $5.28 million a year earlier, the company said. Encorium conducts clinical research for pharmaceutical and biotechnology companies around the world.
November 4, 2000 |
Francis B. O'Brien Jr., 74, a retired physician and researcher, died of lung failure Wednesday at Riddle Village, a retirement community in Middletown. He formerly lived in Newtown Square. Dr. O'Brien had maintained a private practice in obstetrics and gynecology for nearly 20 years early in his career. He had offices in Brooklyn, N.Y., his hometown, and on Long Island. In 1974, he closed his private practice and joined G. D. Searle & Co. in Skokie, Ill., as assistant director of clinical research in obstetrics and gynecology.
November 9, 1998 |
The Fox Chase Cancer Center and Temple University will announce today an agreement that will expand their decade-old joint academic and clinical program to strengthen cancer care services in Greater Philadelphia. But both parties emphasized the expanded agreement, which will run through 2008, is designed to strengthen their affiliation, and isn't a merger. "This affiliation allows both institutions to draw on existing strengths and build new programs, while retaining our independence and separate identities," Fox Chase President Robert C. Young said.
August 7, 2008 |
INDIANAPOLIS - Drug-development services company Covance Inc. will buy an Indiana research center from Eli Lilly and Co. and enter a 10-year service deal with the drugmaker worth $1.6 billion. New Jersey-based Covance will pay $50 million for Lilly's 450-acre drug development campus in Greenfield, Ind., while offering employment to about 260 Lilly employees. Lilly is headquartered in Indianapolis. Covance will use the site to provide mostly early-stage clinical trial work to Lilly as part of the 10-year contract.
August 18, 2013 |
Carly Sokach didn't have much interest in research. For her, it was simply an obligatory requirement for her to apply to medical school. But that changed this summer when the University of Pennsylvania rising junior began working on research that inspired her: She studied whether a questionnaire could tell doctors if a patient with ulcerative colitis was in remission, rather than resorting to a colonoscopy, an invasive procedure. She spent much of her time talking to patients who had the disease.
March 23, 2006 |
Last week, six very healthy men suddenly wound up in a London hospital in critical condition. Earlier this month, 11 otherwise well people tested positive for tuberculosis, according to Montreal's health department. What do these people have in common? All were human subjects in research paid for and conducted by private companies. These problems mean that the time has come to take a closer look at how commercialized research involving human subjects is being conducted all over the world.
April 1, 2011
The good news is that some pharmaceutical companies now disclose payments they make to doctors for speaking engagements or consulting and to researchers, hospitals, and other medical institutions for clinical studies. The bad news is that each company discloses the information differently. That will change as part of the overhaul of the nation's health insurance system, but we won't see the results of that until 2013. For now, we'll need to make do with nonstandard disclosures, such as those released by GlaxoSmithKline P.L.C.